European Parliament Library

Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding, Illustrated with the Technology Transfer of the Drug-Eluting Coronary Stent

Label
Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding, Illustrated with the Technology Transfer of the Drug-Eluting Coronary Stent
Language
eng
Literary Form
non fiction
Main title
Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding
Nature of contents
dictionaries
Oclc number
1273982578
Series statement
Annals of Science and Technology Policy, v.19
Sub title
Illustrated with the Technology Transfer of the Drug-Eluting Coronary Stent
Summary
This study develops a detailed description of the successful technology transfer of an invention -- the drug-eluting coronary stent -- originating in intramural research within the US National Institutes of Health
Table Of Contents
Intro -- Introduction -- A Practical Problem for Publicly-Financed Biomedical Research -- Alternative Solutions for the Practical Problem -- An Overview of the Sections -- The Two Avenues for Public Funding of Pharmaceutical and Other Biomedical R&amp -- D -- The First Avenue of Public Funding -- The Second Avenue of Public Funding -- The Sizes of the Two Avenues of Public Funding -- The Story of Drug-Eluting Coronary Stents -- The Invention of the Drug-Eluting Coronary Stent -- NIH Finds an Ideal Exclusive Licensee for the Technology Transfer of the Drug-Eluting Coronary Stent -- The Successful Commercialization of the Paclitaxel-Eluting Coronary Stent -- The Incentives Issue -- Three Cases for the Effect of Competition on Biomedical R&amp -- D -- Circumstances for Appropriate Incentives for Biomedical R&amp -- D -- The Circumstances Affecting Incentives for the Development of Drug-Eluting Stents -- Scherer's Virtuous Competitive Rent-Seeking -- R&amp -- D Rivalry in the Development of Drug-Eluting Stents -- A Proposal for Government Royalties for Biomedical Products Developed with Substantial Public Funding for R&amp -- D -- Efficiency Implications of Government Royalties -- Government Royalties for the Direct Funding Avenue: Intramural Research -- Government Royalties for the Direct Funding Avenue: Extramural Research -- Government Royalties for the Indirect Funding Avenue -- Conclusion -- Acknowledgements -- Appendices -- Incomplete Pass Through of the Royalty to Price Given Market Power -- About the Authors -- References
resource.variantTitle
Government Royalties on Sales of Pharmaceutical and Other Biomedical Products Developed with Substantial Public Funding
Classification
Contributor
Content
Other version
Mapped to

Incoming Resources